在选择慢性淋巴细胞白血病的第一线治疗中,在指导方针和实际挑战之间的差距上进行导航
1Department of Hematology, Hull University Teaching Hospitals NHS Trust, Hull, UK.
Expert review of hematology
|February 21, 2025
概括
慢性淋巴细胞白血病 (CLL) 的个性化治疗至关重要. 目前的指导方针需要更新,以纳入患者的偏好和现实世界的因素,以获得更好的目标治疗结果,如BTK和BCL-2抑制剂.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 药理学 药理学 是一个学科.
背景情况:
- 慢性淋巴细胞白血病 (CLL) 管理已经从化疗演变为向治疗,包括BTK和BCL-2抑制剂.
- 现有的治疗指南可能无法完全解决患者的偏好,并发性疾病和现实环境中的后勤挑战.
研究的目的:
- 为了解决当前CLL治疗指南的局限性.
- 为前线CLL治疗提出个性化,以患者为中心的决策框架.
主要方法:
- 审查前线CLL治疗中的挑战,重点关注BTK抑制剂和基于venetoclax的疗法.
- 基于遗传标记 (例如TP53突变/del(17p)) 和老年人的评估,对患者分层的检查.
- 考虑伴随性疾病,如心血管疾病和功能障碍.
主要成果:
- 当前的指导方针往往不足以解决现实世界的患者需求和复杂性.
- 为了个性化的CLL护理,需要一个整合临床,遗传和后勤因素的实际框架.
- 患者对口服方案和生活质量的偏好是关键考虑因素.
结论:
- 以患者为中心的方法对于优化CLL治疗决策至关重要.
- 未来的CLL治疗指南应该优先考虑与个体患者需求一致的个性化模型.
- 整合患者特异性因素可以提高CLL管理中的决策和治疗结果.
相关概念视频
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K


